Skip to main content
Figure 4 | BMC Pulmonary Medicine

Figure 4

From: Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial

Figure 4

Change from baseline in dynamic IC at end of exercise at Week 3. Change from baseline in dynamic IC measured before exercise, at isotime, and at end of exercise was assessed at Week 3 (ITT population). Data reported as least squares means change from baseline (analysis of covariance) + standard error; Δ = least squares means difference (95% confidence intervals). ***p < 0.001, ****p < 0.0001 versus placebo. BID, twice daily; IC, inspiratory capacity; ITT, intent-to-treat.

Back to article page